Vanda Pharmaceuticals Q3 2026 net loss narrows 64% from Q2 to $22.6 million; Q3 2026 total revenues rise 24% year over year to $69.8 million
Bitget2026/10/28 20:02- Vanda Pharmaceuticals’ Q3 2026 net loss narrowed 64% from Q2 2026 to $22.6 million.
- Revenue rose 24% year-over-year to $69.8 million, while operating expenses fell 18% from Q2 2026 to $93.3 million.
- BYSANTI’s commercial launch is expected in Q4 2026; Quimilza’s FDA review has a December 12, 2026 target action date.
- Full-year 2026 revenue is expected to exceed $240 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
The White House did not intervene in the decision-making of Nvidia's board of directors.
Crypto prices
More
